Viral Hepatitis

You have full text access to this OnlineOpen article

Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial†‡§

  1. Zachary D. Goodman1,‖,*,
  2. Anne M. Stoddard2,
  3. Herbert L. Bonkovsky3,¶,
  4. Robert J. Fontana4,
  5. Marc G. Ghany5,
  6. Timothy R. Morgan6,8,
  7. Elizabeth C. Wright7,
  8. Elizabeth M. Brunt9,
  9. David E. Kleiner10,
  10. Mitchell L. Shiffman11,
  11. Gregory T. Everson12,
  12. Karen L. Lindsay13,
  13. Jules L. Dienstag14,15,
  14. Chihiro Morishima16,
  15. HALT-C Trial Group

Article first published online: 5 AUG 2009

DOI: 10.1002/hep.23211

Issue

Hepatology

Hepatology

Volume 50, Issue 6, pages 1738–1749, December 2009

Additional Information

How to Cite

Goodman, Z. D., Stoddard, A. M., Bonkovsky, H. L., Fontana, R. J., Ghany, M. G., Morgan, T. R., Wright, E. C., Brunt, E. M., Kleiner, D. E., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Dienstag, J. L., Morishima, C. and HALT-C Trial Group (2009), Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. Hepatology, 50: 1738–1749. doi: 10.1002/hep.23211

Author Information

  1. 1

    Armed Forces Institute of Pathology, Division of Hepatic Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC

  2. 2

    New England Research Institutes, Watertown, MA

  3. 3

    Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT

  4. 4

    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI

  5. 5

    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  6. 6

    Division of Gastroenterology, University of California Irvine, Irvine, CA

  7. 7

    Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  8. 8

    Gastroenterology Service, VA Long Beach Healthcare System, Long Beach, CA

  9. 9

    Department of Pathology and Immunology, Washington University, St. Louis, MO

  10. 10

    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  11. 11

    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA

  12. 12

    Section of Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO

  13. 13

    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA

  14. 14

    Gastrointestinal Unit (Medical Services), Massachusetts General Hospital, Boston, MA

  15. 15

    Department of Medicine, Harvard Medical School, Boston, MA

  16. 16

    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA

  1. Carolinas Medical Center, Charlotte, NC

  1. ‖

    fax: 804-545-9701.

*American International Pathology Laboratories, 8403 Colesville Road, Silver Spring, MD 20910

  1. †

    The opinions and assertions expressed in this study are the private views of the authors and do not represent the views of the National Center for Research Resources, the National Institutes of Health, the Department of the Army, or the Department of Defense.

  2. ‡

    Potential conflict of interest: Dr. Goodman received grants from Schering-Plough, Novartis, and Pharmasset. Dr. Bonkovskyi is a consultant for and advises Boehringer-Ingelheim and Novartis. He also advises and is on the speakers' bureau of Lunbeck Pharma. He received grants from Hoffmann-LaRoche, Merck, and Vertex. Dr. Fontana is on the speakers' bureau of Roche. Dr. Lindsay received grants from Schering-Plough, Valeant, Vertex, and Wyeth. She is also a consultant for and advises Bristol-Myers Squibb, Clinical Care Options, Kendle International, King, Peregrine, Roche Diagnostics, Valeant, Zymogenetics. She received grants from, is a consultant for, and advises, Hoffmann-LaRoche, Human Genome Sciences, and Idenix Pharmaceuticals. Dr. Morgan is a consultant for, is on the speakers' bureau of, and received grants from Roche. He advises and received grants from Vertex. He received grants from Schering-Plough and March. Dr. Shiffman advises and received grants from Biolex, Conatus, Human Genome Sciences, Romark, Valeant, Vertex, and Zymogenetics. He advises Bristol-Myers Squibb, Anadys and Novartis. He received grants from GlaxoSmithKline, Globeimmune, Idenix, Johnson and Johnson, and Wyeth. He is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. He also advises, is on the speakers' bureau of, and received grants from Schering-Plough. Dr. Stoddard owns stock in Elan Corp., Johnson and Johnson, Stryker, Proctor and Gamble, and Bristol-Myers Squibb.

  3. §

    Additional support was provided by Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement with the National Institutes of Health. (See †† for contract and grant details.)

Publication History

  1. Issue published online: 20 NOV 2009
  2. Article first published online: 5 AUG 2009
  3. Accepted manuscript online: 5 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 28 JUL 2009
  5. Manuscript Received: 22 APR 2009

Funded by

  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • National Center for Minority Health and Health Disparities
  • General Clinical Research Center
  • Clinical and Translational Science Center grants from the National Center for Research Resources
  • National Institutes of Health

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1037K)

References

  • 1
    Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. HEPATOLOGY 2003; 38: 493–502.
  • 2
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579–587.
  • 3
    Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484–491.
  • 4
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994; 20: 15–20.
  • 5
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 6
    O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000; 114: 712–718.
  • 7
    Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in chronic hepatitis C: evaluation by morphometric image analysis. HEPATOLOGY 2007; 45: 886–894.
  • 8
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 1449–1457.
  • 9
    McHutchison J, Goodman Z, Maklouf HR, Rodriguez–Torres M, Shiffman ML, Rockey DC, et al. Double-blind, randomized, placebo-controlled, multi-center phase II dose-ranging study to assess the antifibrotic activity of farglitazar in chronic hepatitis C infection. HEPATOLOGY 2008; 48( Suppl): 1139–1140.
  • 10
    Di Bisceglie AM, Schiffman ML, Everson GT, Lindsay KL, Everhardt JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. New Engl J Med 2008; 359: 2429–2441.
  • 11
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472–492.
  • 12
    Skinner HA. Development and validation of a lifetime alcohol consumption assessment procedure. Toronto, Canada: Addiction Research Foundation, 1982.
  • 13
    Shiffman ML, Morishima C, Lindsay KL, Hoefs JC, Dienstag JL, Szabo G, et al.; HALT-C Trial Group. Suppression of serum HCV RNA levels during maintenance peginterferon (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C Trial. J Hepatol 2008; 48( Suppl 2): S62.
  • 14
    Sherman KE, Goodman ZD, Sullivan ST, Faris-Young S. Liver biopsy in cirrhotic patients. Am J Gastroenterol 2007; 102: 789–793.
  • 15
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239–244.
View Full Article (HTML) Get PDF (1037K)